Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors during the central nervous process, conolidine modulates alternate molecular targets. A Science Advancements review located that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability... https://scottp119bdr6.slypage.com/profile